Showing 2721-2730 of 4091 results for "".
- La Roche-Posay's "Dermatologist from the Heart" Accepting Applicationshttps://practicaldermatology.com/news/20140421-la_roche-posays_dermatologist_from_the_heart_accepting_applications/2459264/La Roche-Posay is accepting grant application for its “Dermatologist from the Heart” program in the United States. Now in its second year in the US, “Dermatologist from the Heart” aims to support initiatives designed to enhance the quality of life for patients. Through this program, the La Fon
- FDA Clears Scar Management Gel from Oculus and Quinnovahttps://practicaldermatology.com/news/20131204-fda_clears_scar_management_gel_from_oculus_and_quinnova/2459398/Oculus Innovative Sciences, Inc. has received a new 510(k) clearance from the FDA for Microcyn Scar Management HydroGel, for the management of old and new hypertrophic and keloid scarring resulting from burns, general surgical procedures, and trauma wounds. Oculus U.S. dermatology partner, Quinnova
- ASLMS: CellFX from Pulse Offers Durable Clearance of SH Lesionshttps://practicaldermatology.com/news/aslms-cellfx-from-pulse-offers-durable-clearance-of-sh-lesions/2461183/The CellFX® system from Pulse Biosciences, Inc. demonstrates durable efficacy for the clearance of Sebaceous Hyperplasia lesions, according to data presented at the 2022
- Experts React to FDA Approval of Cabtreo Topical Gel for Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-cabtreo-topical-gel-for-acne-vulgaris/2462087/The U.S. Food and Drug Administration (FDA) has approved CABTREO (clindamycin phosphate, adapalene, and benzoyl peroxide) topical gel for the topical treatment of acne vulgaris in patients aged 12 and older. Bausch Health and Ortho Dermatologics' CABTREO is the first and
- WCD News: Experts Excited About Ornovi’s Next Generation JAK Inhibitorhttps://practicaldermatology.com/news/wcd-news-experts-excited-about-ornovis-next-generation-jak-inhibitor/2461833/Ornovi's OR-101 is a highly selective next generation JAK3-ITK inhibitor with potentially a better safety profile than JAK inhibitors currently on the market, according to a presentation at the 25th World Congress of Dermatology Meeting 2023 in Singapore. Seemal Desa
- Experts React to Approval of Pfizer’s CIBINQO for Teens With Refractory ADhttps://practicaldermatology.com/news/fda-oks-pfizers-cibinqo-for-teens-with-refractory-ad/2461560/The US FDA has approved a supplemental New Drug Application (sNDA) for CIBINQO (abrocitinib, Pfizer). This move expands the drug's indication to include adolescents (12 to < 18 years) with refractory, moderate to severe atopic dermatitis (AD) whose disease is not adequately contr
- Experts Highlight Need to Focus on Psoriasis Patients’ Wellbeing in Practicehttps://practicaldermatology.com/news/experts-highlight-need-to-focus-on-psoriasis-patients-wellbeing-in-practice/2460945/In addition to managing the clinical manifestations of psoriasis, clinical practices should implement an overall and holistic assessment of the wellbeing of each patient, says a panel of scientists speaking at a symposium during the European Association of Dermatology and Venereology (EADV) 30th&
- Sunscreen Chemicals Found in the Bloodstream: Experts React to the New Findingshttps://practicaldermatology.com/news/sunscreen-chemicals-found-in-bloodstream-experts-react-to-the-new-findings/2460023/Several active ingredients found in different sunscreens enter the bloodstream at levels that far exceed the FDA's recommended threshold without a government safety inspection, a new study in Journal of the American M
- Mosquito Virus Expert Discusses a Promising New Drug For Zikahttps://practicaldermatology.com/news/mosquito-virus-expert-discusses-a-promising-new-drug-for-zika/2458257/Thomas Voss, PhD, a world-renowned leader in infectious disease research, and his team, say there are two strategies for developing a defense program against Zika infection: prevention, achieved by developing an effective vaccine and vaccination program or the development of a drug that can kill
- Skin Cancer Expert Perry Robins, MD Joins Emerald's Advisory Boardhttps://practicaldermatology.com/news/skin-cancer-expert-perry-robins-md-joins-emeralds-advisory-board/2458574/New York City dermatologist Perry Robins, MD has joined Emerald Medical Applications Corp.’s advisory board. Emerald, an Israeli-based company, is developing DermaCompare™, a proprietary artificial intelligence free app